The 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference 2024 was held in Boston, MA on 20-21 June, 2024. The event brought together academics and scientists from research institutes and biopharmaceutical companies to discuss the latest updates, challenges, and future directions in immuno-oncology research. Topics discussed included:
Updates in development of ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Biomarkers and Personalized Medicine in IO
CAR-T Cell therapy, TCR Based-Cell Therapy
Tumor microenvironment and Oncolytic Viruses
→ Biointron’s Highlighted Points:
1. Antibody Therapy Developments
Anchored immunotherapy within the tumor microenvironment results in prolonged drug retention and limited systemic toxicity; aluminium hydroxide as a stable anchoring scaffold.
Potential side effects of immunotherapies and best safety practices for managing them were discussed. (@Indaptus Therapeutics)
B7-H7, a novel checkpoint axis for therapeutic targeting in cancer, suppresses T and NK cell activation through a novel immunosuppressive receptor.
Many of the recently approved or investigated approaches for melanoma immunotherapy require more answers to develop and enhance effective memory response against cancer cells.
2. Pre-clinical and Translational IO & Immune Checkpoint Blockades
Polyploid giant cancer cells (PGCCs) are responsible for tumor progression, metastasis, chemoresistance and relapse. Key molecular pathways, therapeutic strategies, and computational methods were discussed.
Challenges and opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination; challenges to attaining the best therapeutic index.
Intrinsic differences in tumor biology due to post translation modifications and protein-protein interactions lead to racial disparity in breast cancer - understanding this can help in designing precision medicines.
Novel antibody-enabled targeted protein stabilization (TPS2) augments anti-tumor immune response by delivering Cbl-b inhibitor to immune cells while blocking checkpoint molecule, PD1.
Thank you for visiting us at our booth in NGIO 2024 to learn about our services! We had a great time connecting with you and understanding how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
